Crossmark

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Crossref DOI link: https://doi.org/10.1186/s40880-016-0154-7

Published Online: 2016-10-28

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pang, Xiufeng http://orcid.org/0000-0002-4271-8710
Liu, Mingyao
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China (81672758)

the Science and Technology Commission of Shanghai Municipality (16ZR1410400, 14DZ2270100)

the Fundamental Research Funds for the Central Universities (78260029)